GL
XBI icon

Graypoint LLC’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Graypoint LLC’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,771
Closed -$225K – 549
2025
Q1 		$225K Buy
2,771
+1
+0% +$89 0.01% 473
2024
Q4 		$250K Buy
2,770
+32
+1% +$3.1K 0.02% 444
2024
Q3 		$271K Buy
2,738
+146
+6% +$14.3K 0.02% 420
2024
Q2 		$240K Buy
2,592
+22
+0.9% +$1.97K 0.02% 423
2024
Q1 		$244K Buy
+2,570
New +$238K 0.02% 408
2023
Q3 		– Sell
-3,589
Closed -$299K – 429
2023
Q2 		$299K Buy
3,589
+142
+4% +$11.9K 0.03% 309
2023
Q1 		$263K Buy
3,447
+231
+7% +$19.2K 0.03% 303
2022
Q4 		$267K Buy
3,216
+79
+3% +$6.4K 0.03% 286
2022
Q3 		$249K Buy
3,137
+58
+2% +$4.89K 0.03% 281
2022
Q2 		$229K Sell
3,079
-100
-3% -$7.51K 0.03% 268
2022
Q1 		$286K Buy
+3,179
New +$294K 0.03% 270

Other funds holding XBI

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BC
Broadwater Capital Boston, Massachusetts $134M AUM 21.11% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Graypoint LLC's XBI Position: Q2 2025 in Review

Graypoint LLC sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2025, closing a stake of 2,771 shares — an estimated $225K sold.

Graypoint LLC first reported a position in XBI in Q1 2022 and held it in 11 quarters. The position peaked at $299K in Q2 2023. 625 funds tracked by Wall St. Rank hold XBI as of Q2 2025.

  • Graypoint LLC reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2025 after selling out during the quarter.
  • Graypoint LLC sold 2,771 State Street SPDR S&P Biotech ETF shares in Q2 2025, an estimated $225K.
  • Graypoint LLC first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and held it in 11 quarters.
  • Graypoint LLC's State Street SPDR S&P Biotech ETF position peaked at $299K in Q2 2023.
  • 625 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2025.

Based on Graypoint LLC's 13F filing for Q2 2025, filed 15 Jul 2025.